|[January 07, 2014]
OncoSec Medical to Present Corporate Update at Biotech Showcase 2014
SAN DIEGO --(Business Wire)--
OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing
its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid
tumors, today announced that Punit Dhillon, President and CEO, will
provide a corporate update at Biotech Showcase 2014; one of the world's
largest life sciences conferences held annually in San Francisco.
The presentation is scheduled to take place on Tuesday, January 14 at
2:30 p.m. PST at the Parc 55 Wyndham San Francisco-Union Square, located
at 55 Cyril Magnin Street. A live webcast will be available by visiting
the following link: http://www.media-server.com/m/p/byw47js4.
About Biotech Showcase 2014
Biotech Showcase™ is an investor and partnering conference devoted to
providing private and public biotechnology and life sciences companies
with an opportunity to present to, and meet with, investors and
pharmaceutical executives in one place during the course of one of the
industry's largest annual healthcare investor conferences. Investors and
biopharmaceutical executives from around the world gather in San
Francisco during this critical week, which is widely viewed as setting
the tone for the coming year.
Now in its sixth yar, Biotech Showcase is expected to attract upwards
of 1,700 attendees. The program includes lunch plenary sessions
featuring top industry leaders and innovators speaking on industry and
time-relevant topics, as well as presentations from both private and
About OncoSec Medical Inc.
OncoSec Medical Inc. is�a biopharmaceutical company�developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors.�ImmunoPulse and NeoPulse therapies�address an
unmet medical need.�They represent�a potential solution, for less
invasive and less expensive therapies and can potentially minimize the
detrimental effects of current cancer treatments such as surgery,
systemic chemotherapy and other treatment alternatives. OncoSec
Medical's core technology is based on its proprietary�use of
an�electroporation platform to enhance�the�delivery and uptake of a
locally delivered DNA-based immunocytokine (ImmunoPulse) or
chemotherapeutic agent�(NeoPulse). Treatment of�various solid
cancers�using these targeted�anti-cancer agents�has
demonstrated�selective destruction of cancerous cells�while potentially
sparing healthy normal tissues during early and late stage clinical
trials. OncoSec's clinical programs include three Phase II clinical
trials for ImmunoPulse targeting lethal skin cancers. More information
is available at�http://www.oncosec.com/.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical's filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
[ InfoTech Spotlight's Homepage ]